What the research found
Tesamorelin, a growth-hormone-releasing hormone analog, is the only compound in common muscle-peptide stacks with rigorous Phase III human evidence. It demonstrably reduces visceral fat and increases lean body mass—but only in adults with HIV-associated lipodystrophy, not healthy younger populations. The mechanism is sound; the direct proof in your target population is not.
MK-677 (ibutamoren), a ghrelin mimetic, has the strongest evidence in healthy people: a two-year double-blind trial in 65 older adults showed it restored growth hormone and IGF-1 to young-adult levels and added 1.1 kg of fat-free mass versus a 0.5 kg loss in placebo. The problem: strength and function did not improve. Much of the mass gain was intracellular water and body cell mass rather than contractile muscle fiber you can train with. Merck discontinued development after functional endpoints repeatedly failed.
CJC-1295 + ipamorelin, the most widely prescribed peptide stack, has no controlled human trials showing body-composition, strength, or muscle-size changes in healthy training adults. Single-dose pharmacokinetic studies confirm it triggers growth-hormone pulses, but that is where the evidence stops. Everything beyond that is extrapolation from hormone curves. Below this, the hierarchy collapses: IGF-1 LR3 has virtually no controlled human data; BPC-157 and TB-500 are recovery compounds miscategorized as hypertrophy agents.
Why it matters for you
If you are using peptides to build muscle, you are making a bet on mechanism rather than outcome. A rising GH or IGF-1 on your bloodwork is not equivalent to gaining strength or muscle you can measure on the bar or with a tape. MK-677 illustrates this plainly: it worked exactly as advertised hormonally but did not translate to functional muscle in the best trial ever run on it.
The implication for your protocol is practical. If you are tracking peptide efficacy by biomarkers alone—GH secretion tests, IGF-1 levels—you are tracking only half the equation. You need independent confirmation through training metrics (strength gains, hypertrophy) and body composition (DEXA lean mass, not just scale weight). Water retention and cellular hydration can inflate the number without building the muscle.
For users considering the most common stacks, the honest position is that you are experimenting on an outcome that has not been formally measured in your population. That is not an argument against trying—mechanism-based reasoning is legitimate—but it is an argument for setting realistic expectations and measuring what actually matters to you, not just what moves on a lab report.
Caveats
- Tesamorelin evidence is disease-specific: trials were in HIV-lipodystrophy, not healthy populations; mechanism may not translate identically
- MK-677 trial used older adults: population was 65+ with likely lower baseline muscle mass and training stimulus; results may not apply to younger, trained individuals
- CJC-1295 + ipamorelin lack any controlled body-composition trials in any population; all claims rest on pharmacokinetic plausibility
- Most lower-tier peptides (IGF-1 LR3, BPC-157) have minimal or zero rigorous human data for muscle building
- No head-to-head comparative trials exist; ranking is based on whatever human data exists, not direct efficacy comparison